Last reviewed · How we verify

NCT04246892: ALADIN

Impact of Alarm Reduction on Delirium in ICU

Terminated Last updated 30 August 2023
What this trial tests

trial in Delirium in 89 participants. Terminated before completion.

Timeline
3 February 2020
Primary endpoint
23 February 2023
23 February 2023

Quick facts

Lead sponsorCentral Hospital, Nancy, France
StatusTerminated
Study typeOBSERVATIONAL
Enrollment89
Start date3 February 2020
Primary completion23 February 2023
Estimated completion23 February 2023
Sites1 location across France

Conditions studied

Sponsor

Central Hospital, Nancy, France

Who can join

18 and older, any sex, with Delirium. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Delirium is an acute and fluctuating disturbance of consciousness and can occur in 80% of critically ill patients. Delirium is more frequent in mecanically ventilated patients and is associated with longer hospital stay, increased cognitive impairment and mortality. On the occasion of the change of the monitors in the ICU ward, allowing a total withdrawal of alarms in patients room, this study evaluates the prevalence of delirium before and after the alarm withdrawal. During the first period the patients will be monitored as usual, and during the second period patients will be monitored without alarms ringing in patients room. Delirium will be screened with a validated, clinical tool.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Delirium

Currently open trials in the same condition.

Other Central Hospital, Nancy, France trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04246892.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing